Mundipharma Announces Positive Topline Results From Phase III ReSPECT Trial Assessing ▼REZZAYO® (Rezafungin) for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Haematopoietic Stem Cell Transplantation Patients

Key Takeaways

• Rezafungin met primary endpoint, non‑inferior to standard regimen (60.7% vs 59.0%).
• Once‑weekly dosing lowered drug‑drug interactions and treatment discontinuations.
• Safety comparable; fewer dose reductions and study drug withdrawals observed.
• Mundipharma plans sNDA submission to FDA in H2 2026.
• Trial spanned 50+ centers across seven countries, enrolling high‑risk HSCT patients.

Pulse Analysis

Invasive fungal diseases (IFDs) remain a leading cause of morbidity and mortality among patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Immunosuppression, prolonged neutropenia, and mucosal barrier injury create a perfect storm for opportunistic pathogens such as Candida, Aspergillus and Pneumocystis. Existing prophylactic regimens often require daily dosing and carry significant drug‑drug interaction (DDI) risks, especially in patients already on complex immunosuppressive protocols. Rezafungin, a next‑generation echinocandin with a long half‑life, enables once‑weekly administration, potentially reducing pill burden and DDI exposure while maintaining potent antifungal activity.

The global ReSPECT Phase III trial, the largest of its kind for antifungal prophylaxis, enrolled adult HSCT recipients across more than 50 sites in seven countries. Rezafungin achieved a fungal‑free survival rate of 60.7% at Day 90, meeting the non‑inferiority margin against the standard antimicrobial regimen (59.0%). Secondary endpoints reinforced its advantage: fewer treatment‑emergent adverse events led to dose reductions or discontinuations, and overall safety was on par with the comparator. These findings suggest rezafungin can deliver comparable efficacy with a more convenient dosing schedule and a cleaner safety profile, attributes that could shift prescribing habits in transplant centers.

Regulatory momentum is now the next hurdle. Mundipharma and its U.S. partner CorMedix aim to file a supplemental New Drug Application in the second half of 2026, with an EMA submission slated for Q3 2026. If approved, rezafungin would join a limited class of antifungals offering weekly dosing, positioning Mundipharma to capture a premium segment of the prophylaxis market. The product could also serve as a platform for future indications, leveraging its favorable PK/PD characteristics to address other high‑risk immunocompromised populations, thereby expanding both clinical impact and commercial upside.